Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.

European Journal of Heart Failure
Gianluigi SavareseLars H Lund

Abstract

Renin-angiotensin-aldosterone system inhibitors (RAASi) improve outcomes in cardiorenal disease but concerns have been raised over increased risk of incident hospitalization and death from coronavirus disease 2019 (COVID-19). We investigated the association between use of angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs) or mineralocorticoid receptor antagonists (MRAs) and COVID-19 hospitalization/death in a large nationwide population. Patients with hypertension, heart failure, diabetes, kidney disease, or ischaemic heart disease registered in the Swedish National Patient Registry until 1 February 2020 were included and followed until 31 May 2020. COVID-19 cases were defined based on hospitalization/death for COVID-19. Multivariable logistic and Cox regressions were fitted to investigate the association between ACEi/ARB and MRA and risk of hospitalization/death for COVID-19 in the overall population, and of all-cause mortality in COVID-19 cases. We performed consistency analysis to quantify the impact of potential unmeasured confounding. Of 1 387 746 patients (60% receiving ACEi/ARB and 5.8% MRA), 7146 (0.51%) had incident hospitalization/death from COVID-19. After adjustment for 45 variable...Continue Reading

References

Jan 18, 2007·JAMA : the Journal of the American Medical Association·Ralph B D'Agostino, Ralph B D'Agostino
Jan 16, 2016·European Journal of Epidemiology·Jonas F LudvigssonWeimin Ye
Aug 3, 2017·The New England Journal of Medicine·Thomas R Frieden
Sep 16, 2019·International Journal of Cardiology·Gianluigi SavareseLars H Lund
Feb 20, 2020·The New England Journal of Medicine·Marc LipsitchLyn Finelli
Apr 1, 2020·The New England Journal of Medicine·Muthiah VaduganathanScott D Solomon
Apr 18, 2020·Circulation Research·Venkatesh L MurthyRavi V Shah
May 2, 2020·The New England Journal of Medicine·Giuseppe ManciaGiovanni Corrao
May 2, 2020·The New England Journal of Medicine·Harmony R ReynoldsJudith S Hochman
Jun 13, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Sophie LiabeufValérie Gras-Champel
Jun 20, 2020·JAMA : the Journal of the American Medical Association·Emil L FosbølLars Køber

❮ Previous
Next ❯

Citations

Jan 10, 2021·European Journal of Heart Failure·Daniela TomasoniMarco Metra
Dec 23, 2020·Journal of Occupational and Environmental Medicine·Marcos C BaptistaGlenn Pransky
Mar 12, 2021·Frontiers in Physiology·Simon B GressensEmmanuelle Vidal-Petiot
Apr 15, 2021·Clinics·Filipe FerrariRicardo Stein
Apr 30, 2021·European Journal of Heart Failure·Matteo PagnesiMarco Metra
May 19, 2021·Journal of Neurology·Heather Angus-LeppanRoberto J Guiloff
Jul 16, 2021·European Journal of Heart Failure·Gianluigi SavareseMarco Metra
Jul 30, 2021·Journal of the American Heart Association·Jordan LoaderJohan Sundström
Sep 12, 2021·Journal of Human Hypertension·Marijana Tadic, Cesare Cuspidi

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Software Mentioned

R

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.